Project Umbrella Translation
TRIAL DRUG REFINEMENT FILE
Regarding Trial Drug AT1521
Trial Drug AT1521 (henceforth AT) was designed for the purpose of dramatically delaying and suppressing pathogenesis in individuals infected with the T-Virus.
AT is a trial drug effective only if administered before an individual exhibits symptoms. It does not eliminate the virus' presence itself, only "inhibits" it.
Nevertheless, this trial agent is enormously powerful. In experiments with mice, it successfully suppressed the virus with a high probability of 99.1%. This may be the only means of resisting "T," from which 100% recovery is virtually impossible if symptoms develop.
Written below are the procedures for refining the trial agent.
Note that it is forbidden for this file to leave the facility without a special reason.
Michael Jenkins
<The next dozens of pages contain special chemical formulas>
Regarding Trial Drug AT1521
Trial Drug AT1521 (henceforth AT) was designed for the purpose of dramatically delaying and suppressing pathogenesis in individuals infected with the T-Virus.
AT is a trial drug effective only if administered before an individual exhibits symptoms. It does not eliminate the virus' presence itself, only "inhibits" it.
Nevertheless, this trial agent is enormously powerful. In experiments with mice, it successfully suppressed the virus with a high probability of 99.1%. This may be the only means of resisting "T," from which 100% recovery is virtually impossible if symptoms develop.
Written below are the procedures for refining the trial agent.
Note that it is forbidden for this file to leave the facility without a special reason.
Michael Jenkins
<The next dozens of pages contain special chemical formulas>
Official Japanese Transcript
試薬精製ファイル
試薬AT1521について
試薬AT1521（以下AT）は、Tウィルスに感染した個体に対し、その発症を劇的に遅延・抑制させる目的で作られたものである。
ATは、発症前の個体に対してのみ有効な試薬である。ウィルスの存在そのものを消し去る効果はなく、あくまで「抑制」なのだ。
とはいえ、この試薬の威力は絶大だ。マウスによる実験では、99.1%という高確率で抑制に成功した。発症すればほぼ100%回復の見込みのない「T」に対する、唯一の抵抗手段となろう。
試薬の精製方法について以下に記す。
なおこのファイルは特別な理由がない限り、施設外への持ち出しを禁ずる。
マイケル・ジェンキンス
＜以下数十ページにわたり、専門的な化学式が記されている＞
試薬AT1521について
試薬AT1521（以下AT）は、Tウィルスに感染した個体に対し、その発症を劇的に遅延・抑制させる目的で作られたものである。
ATは、発症前の個体に対してのみ有効な試薬である。ウィルスの存在そのものを消し去る効果はなく、あくまで「抑制」なのだ。
とはいえ、この試薬の威力は絶大だ。マウスによる実験では、99.1%という高確率で抑制に成功した。発症すればほぼ100%回復の見込みのない「T」に対する、唯一の抵抗手段となろう。
試薬の精製方法について以下に記す。
なおこのファイルは特別な理由がない限り、施設外への持ち出しを禁ずる。
マイケル・ジェンキンス
＜以下数十ページにわたり、専門的な化学式が記されている＞
Official English Transcript
"Due to errors or changes in localization, the following may contain inconsistencies with the official Japanese text."
REAGENT REFINEMENT FILE
Concerning AT1521:
The reagent known as AT1521 (hereby referred to s "AT") is designed to slow the spread of the T-Virus in infected individuals.
AT is only effective in those who have yet to exhibit symptoms of the virus. It does not eliminate the virus already in the bloodstream, but only suppresses it and slows its progress.
AT has enjoyed a 99.91% success rate in lab mice. Against the T-Virus, which has no actual cure, it remains the only method of control and suppression available.
Details on its refinement are listed below. Only under the most extreme of circumstances is this information allowed to leave company grounds.
Michael Jenkins
REAGENT REFINEMENT FILE
Concerning AT1521:
The reagent known as AT1521 (hereby referred to s "AT") is designed to slow the spread of the T-Virus in infected individuals.
AT is only effective in those who have yet to exhibit symptoms of the virus. It does not eliminate the virus already in the bloodstream, but only suppresses it and slows its progress.
AT has enjoyed a 99.91% success rate in lab mice. Against the T-Virus, which has no actual cure, it remains the only method of control and suppression available.
Details on its refinement are listed below. Only under the most extreme of circumstances is this information allowed to leave company grounds.
Michael Jenkins